News Releases

Date Title and Summary
Sep 14, 2023 Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21, 2023 .  The
Aug 03, 2023 Artivion Reports Second Quarter 2023 Financial Results
Second Quarter and Recent Business Highlights: Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a GAAP and non-GAAP constant currency basis Net loss was ($3.4) million or ( $0.08 ) per share; non-GAAP net
Aug 01, 2023 Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Aug. 1, 2023 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in three upcoming investor conferences.     Artivion's management team will present at the upcoming Canaccord
Jul 20, 2023 Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results
ATLANTA , July 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2023 financial results will be released on Thursday, August 3, 2023 after the market closes.
May 23, 2023 Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA , May 23, 2023 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery
May 04, 2023 Artivion Reports First Quarter 2023 Financial Results
First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis On-X revenues increased 23% on a GAAP basis
Apr 20, 2023 Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results
ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial results will be released on Thursday, May 4, 2023 after the market closes.
Apr 10, 2023 Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference
ATLANTA , April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22 nd Annual Needham Virtual Healthcare Conference .
Mar 06, 2023 Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference
ATLANTA , March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 33 rd Annual Healthcare Conference.
Feb 16, 2023 Artivion Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of 2021, flat on a GAAP basis and an increase of 5% on a non-GAAP constant currency basis Achieved revenue of $313.8 million for the full year of
Displaying 1 - 10 of 11